Anticoagulation

Monika Bhandari , Akshyaya Pradhan , Pravesh Vishwakarma , et al

Read time: 27m 35s
CRT 2025 Meeting Unveils its Late-Breaking Scientific Programme

CRT 2025

AF Symposium 25: LAAC Vs Oral Anticoagulation After Catheter Ablation

Walid Saliba

Watch time: 5m 35s
AHA 24: The OPTION Trial

Oussama M Wazni

Watch time: 5m 15s
TCT 24: The PEERLESS Trial

Dr Wissam A Jaber

Watch time: 6m 16s

Nazli Okumus , Ashley Park , Eugene Yuridistky , et al

Read time: 29m 12s

Mahmoud Izraiq , Nail Alshoubaki , Omran A Abu-Dhaim , et al

Read time: 7m 43s

Mario DiazNuila-Alcazar , Daniel Valcárcel-Paz , Pablo Del Castillo-Vásquez , et al

Read time: 8m 20s
ESC 24: The POPular PAUSE TAVI Trial

Dirk-Jan van Ginkel

Watch time: 7m 9s
ESC 24 Hot Line Discussion: The OCEANIC-AF Trial

Manesh R Patel, Harriette Van Spall

Watch time: 8m 47s
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD

Gi-Byoung Nam, Min Soo Cho

Watch time: 6m 48s
ESC 24: Day 2 Wrap-Up with Dr Alasnag and Dr Al-Shaibi

Mirvat Alasnag, Khaled Al-Shaibi

Watch time: 23m 2s

Darren Mylotte, Marie-Claude Morice, Roisin Colleran, et al

Watch time: 28m 31s (3 videos)

Sonika Malik , Anju Bhardwaj , Matthew Eisen , et al

Andreas Goette , Hein Heidbuchel

Robert F Storey, Dominick J Angiolillo, Christopher P Cannon, et al

Watch time: 1h 32m 8s (5 videos)

Marco Valgimigli, Eliano Navarese, Pascal Vranckx et al

Watch time: 1h 48m 18s (11 videos)

Broadcast

Anticoagulation

Standards & Guidelines
What’s New in the European ACS Guidelines and How Will My Practice Change?

Robert F Storey, Dominick J Angiolillo, Christopher P Cannon, et al

Watch time: 1h 32m 36s

Balen Abdulrahman , Richard J Jabbour , Nick Curzen

Read time: 18m
The Parallax Podcast

Ankur Kalra

Kerry Layne , Albert Ferro

Stuart J Head , Ad JJC Bogers , A Pieter Kappetein

Julia Sikorska , James Uprichard

Broadcast

Anticoagulation
Prioritising Risk in CAD: A Patient-First Discussion

Felicita Andreotti, Diana Gorog, Marco Valgimigli, et al

Watch time: 1h 30m 44s

Media

Marco Valgimigli, Diana Gorog, Eliano Navarese, et al

AHA 23: 3 Trials That Will Change My Practice

Dipti Itchhaporia

Watch time: 7m 20s
View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen

Watch time: 23m 13s
CardioNerds @AHA23: AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF

Naima Maqsood, Christian Ruff

Watch time: 10m 36s

Broadcast

Anticoagulation
Prioritising Risk in CAD: A Patient-First Discussion

Felicita Andreotti, Diana Gorog, Marco Valgimigli, et al

Watch time: 1h 30m 44s

Robert F Storey, Dominick J Angiolillo, Christopher P Cannon, et al

Watch time: 1h 32m 8s (5 videos)

Nicolas M Van Mieghem, Joost Daemen

Watch time: 1h 35m 42s (16 videos)
ESC 23: MULTISTARS AMI Trial

Linda Joosten

Watch time: 4m 9s
ESC 23: The PUSH-AHF Study

Paulus Kirchhof

Watch time: 3m 42s

Yugo Yamashita

Marco Valgimigli, Eliano Navarese, Pascal Vranckx et al

Watch time: 1h 48m 18s (11 videos)

Broadcast

Anticoagulation

Standards & Guidelines
Clopidogrel or Ticagrelor: Why, When, for Whom?

Diana Gorog, Sotiris Antoniou , Franco Cheng, et al

Watch time: 59m 32s

Media

HFA 2018 by Dr Kelley Branch

Kelley Branch

Watch time: 5m 18s
View From the Thoraxcenter: What's Hot at TCT 2018

Nicolas M Van Mieghem, Joost Daemen

Watch time: 18m 45s
View from the Thoraxcenter: ESC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen

Watch time: 24m 27s
ESC 22: COVID-PACT: Antithrombotic Therapy in Critically Ill COVID-19 Pts

David Berg

Watch time: 4m 51s
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19

Sanjit Jolly

Watch time: 4m 59s
ESC 22: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID

Renato D Lopes

Watch time: 3m 57s
ESC 23: The ONCO DVT Study

Yugo Yamashita

Watch time: 4m 8s

Nicolas M Van Mieghem, Joost Daemen

Watch time: 1h 35m 42s (16 videos)
AHA 23: 3 Trials That Will Change My Practice

Dipti Itchhaporia

Watch time: 7m 20s
Parallax: The Year 2023 in Review with Dr Sukh Nijjer

Ankur Kalra, Sukhjinder Nijjer

Watch time: 1h 5m 20s

Finn Gustafsson

Watch time: 7m 19s

Broadcast

Anticoagulation

Heart Failure
How to personalize NOAC for special populations and special situations

Gheorghe-Andrei Dan

Watch time: 1h 12m 28s

Articles

New Antiplatelet Drugs in Perspective

Diego Penela

,

Maríbel Diaz-Ricart

,

Magda Heras

,

Citation:

European Cardiology 2011;7(3):216–9

DOI:

https://doi.org/10.15420/ecr.2011.7.3.216
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 1104
  • Downloads: Downloads 4

New Drugs for Thromboembolic Prevention in Atrial Fibrillation

Jose L Merino

,

José López-Sendón

,

Citation:

European Cardiology 2010;6(4):64–9

DOI:

https://doi.org/10.15420/ecr.2010.6.4.64
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 678
  • Downloads: Downloads 5

Management of Haemostasis with Combined Use of Vascular Closure Devices and Bivalirudin - A Review

Emanuela de Cillis

,

Giuseppe Sangiorgi

,

Alessandro Santo Bortone

,

Citation:

Interventional Cardiology 2011;6(2):177–81

DOI:

https://doi.org/10.15420/icr.2011.6.2.177
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 925
  • Downloads: Downloads 5

Low Revascularisation Rates and Relatively High Stent Thrombosis Rate After Implantation of Drug eluting Stents in High-risk Patients

Jacques Machecourt

,

Citation:

European Cardiovascular Disease 2007;3(1):92–4

DOI:

https://doi.org/10.15420/ecr.2007.0.1.92
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 318
  • Downloads: Downloads 4